RESUMEN
Tumor dissemination via blood to distant organs is the main cause of death. Therefore, there is a critical need to set up sensitive methods for the early detection of circulating tumor cells[CTCs] and disseminated tumor cells[DTCs] in peripheral blood [PB] and bone marrow[BM] specimens of breast cancer patients. The aim of this research is to study the detection of micrometastasis using MUC2 in such patients. In this study, PB and BM samples were collected from 50 breast cancer patients after operation and before adjuvant therapy. Mucin 2 [MUC2] was used as a tumor marker and its transcript level in the sample patients was analyzed using gene specific, quantitative real-time PCR reaction with SYBR Green technology. Samples from 20 healthy individuals were used as negative controls. HPRT was used as a reference gene. MUC2 mRNA was detected in 8 [16%] of PB and BM samples. MUC2 mRNA was not detected in PB samples of healthy individuals. The relapse rate among MUC2-positive patients was higher than MUC2-negative patients; and it was statistically significant in BM [P<0.05]. This study shows that MUC2 can be a suitable marker for the detection of micrometastasis in breast cancer patients at early stages of cancer and that it may provide the basis for identifying women at risk of relapse